Show simple item record

dc.contributor.authorFitzGerald, Liesel M.en_US
dc.contributor.authorAgalliu, Iliren_US
dc.contributor.authorJohnson, Karynnen_US
dc.contributor.authorMiller, Melinda A.en_US
dc.contributor.authorKwon, Erika M.en_US
dc.contributor.authorHurtado-Coll, Antonioen_US
dc.contributor.authorFazli, Ladanen_US
dc.contributor.authorRajput, Ashish, B.en_US
dc.contributor.authorGleave, Martin E.en_US
dc.contributor.authorCox, Michael E.en_US
dc.contributor.authorOstrander, Elaine A.en_US
dc.contributor.authorStanford, Janet L.en_US
dc.contributor.authorHuntsman, David G.en_US
dc.date.accessioned2010-05-06T20:02:23Z
dc.date.available2010-05-06T20:02:23Z
dc.date.issued2008en_US
dc.identifier.citationFitzGerald L, Agalliu I, Johnson K, et al. Association of TMPRSS2-ERG gene fusion with clinical characteristics and outcomes: results from a population-based study of prostate cancer. BMC Cancer. 2008;8(1):230.en_US
dc.identifier.other10.1186/1471-2407-8-230en_US
dc.identifier.urihttp://www.biomedcentral.com/1471-2407/8/230en_US
dc.identifier.urihttp://hdl.handle.net/1773/15811
dc.description.abstractBackground: The presence of the TMPRSS2-ERG fusion gene in prostate tumors has recently been associated with an aggressive phenotype, as well as recurrence and death from prostate cancer. These associations suggest the hypothesis that the gene fusion may be used as a prognostic indicator for prostate cancer. Methods: In this study, fluorescent in situ hybridization (FISH) assays were used to assess TMPRSS2-ERG fusion status in a group of 214 prostate cancer cases from two population-based studies. The FISH assays were designed to detect both fusion type (deletion vs. translocation) and the number of fusion copies (single vs. multiple). Genotyping of four ERG and one TMPRSS2 SNPs using germline DNA was also performed in a sample of the cases (n = 127). Results: Of the 214 tumors scored for the TMPRSS2-ERG fusion, 64.5% were negative and 35.5% were positive for the fusion. Cases with the TMPRSS2-ERG fusion did not exhibit reduced prostate cancer survival (HR = 0.92, 95% CI = 0.22-3.93), nor was there a significant difference in causespecific survival when stratifying by translocation or deletion (HR = 0.84, 95% CI = 0.23-3.12) or by the number of retained fusion copies (HR = 1.22, 95% CI = .45-3.34). However, evidence for reduced prostate cancer-specific survival was apparent in those cases whose tumor had multiple copies of the fusion. The variant T allele of the TMPRSS2 SNP, rs12329760, was positively associated with TMPRSS2-ERG fusion by translocation (p = 0.05) and with multiple copies of the gene fusion (p = 0.03). Conclusion: If replicated, the results presented here may provide insight into the mechanism by which the TMPRSS2-ERG gene fusion arises and also contribute to diagnostic evaluations for determining the subset of men who will go on to develop metastatic prostate cancer.en_US
dc.description.sponsorshipThis work was supported by NIH grants RO1 CA56678, RO1 CA114524, and P50 CA97186; additional support was provided by the Fred Hutchinson Cancer Research Center and the Intramural Program of the National Human Genome Research Institute.en_US
dc.language.isoen_USen_US
dc.titleAssociation of TMPRSS2-ERG gene fusion with clinical characteristics and outcomes: results from a population-based study of prostate canceren_US
dc.typeArticleen_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record